Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease – analyses from VERTIS CV, a randomized trial of the SGLT2 inhibitor ertugliflozin
Corbin KD, Dagogo-Jack S, Cannon CP, et al.
Diabetes Obes Metab. 2022 Nov 17.
Leggi